MIP Diagnostics: Synthetic antibodies to increase accuracy of COVID-19 antigen tests

MIP Diagnostics, which produces synthetic antibodies, has launched a new product that could improve the success of rapid sensors in detecting COVID-19.

MIP Diagnostics has today announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices.

nanoMIPs are nanoscale Molecularly Imprinted Polymers, commonly known as synthetic antibodies. They are manufactured around a template molecule in a highly controlled chemical process. In this case, the nanoMIP has been manufactured around the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, specific to the COVID-19 virus.

Stephane Argivier, Managing Director at MIP Diagnostics Ltd. said of the launch, “We are extremely excited to introduce a solution that will drive improvements to COVID-19 rapid test sensitivity. As the industry has learned, it is extremely important that accurate testing results during the full lifecycle of the infection are achieved, and high sensitivity COVID-19 sensors will enable this.’

He added, ‘The robust characteristics of nanoMIPs and chemical manufacturing processes also introduce a new level of supply consistency and security for device manufacturers that is difficult to achieve with biological receptors. This is especially important for COVID-19 antigen tests because of the huge demand and rapid manufacturing requirements we are currently seeing in the marketplace.”

The MIP Diagnostics Ltd. COVID-19 nanoMIP samples are  now available for diagnostic sensor developers to test.